Embecta Corp. ( EMBC ) NASDAQ Global Select

Cena: 11.5 ( -1.12% )

Aktualizacja 07-24 17:58
NASDAQ Global Select
Branża: Drug Manufacturers - Specialty & Generic
Statystyki
Dywidendy
Rekomendacje
Wyceny
Wskaźniki
Analiza techniczna

Notowania:

Opis firmy:

Embecta Corp., firma medyczna, koncentruje się na zapewnieniu różnych rozwiązań w celu zwiększenia zdrowia i dobrego samopoczucia osób żyjących z cukrzycą. Jego produkty obejmują igły, strzykawki i urządzenia bezpieczeństwa, a także aplikacje cyfrowe, które pomagają osobom w zarządzaniu cukrzycą. Firma sprzedaje swoje produkty przed hurtownikami i dystrybutorami w Stanach Zjednoczonych i na arenie międzynarodowej. Embecta Corp. został założony w 1924 roku i ma siedzibę w Parsippany, New Jersey. Embecta Corp. (NASDAQGS: EMBC) działa niezależnie od Becton, Dickinson and Company na dzień 1 kwietnia 2022 r.

Informacje o spółce:
Sektor: Zdrowie
Branża: Drug Manufacturers - Specialty & Generic
Zatrudnienie: 2 200
Giełda: NASDAQ Global Select
Ilość akcji w obrocie: 95.9947
Ilość akcji: Brak danych
Debiut giełdowy: 2022-03-22
WWW: https://www.embecta.com
CEO: Mr. Devdatt Kurdikar
Adres: 300 Kimball Drive
Siedziba: 07054 Parsippany
ISIN: US29082K1051
Wskaźniki finansowe
Kapitalizacja (USD) 672 088 865
Aktywa: 1 285 300 000
Cena: 11.5
Wskaźnik Altman Z-Score: 1.5
Słaby (wysokie ryzyko bankructwa)
Dywidenda: 1
P/E: 12.9
Ilość akcji w obrocie: 96%
Średni wolumen: 637 322
Ilość akcji 58 442 510
Wskaźniki finansowe
Przychody TTM 1 123 100 000
Zobowiązania: 2 023 600 000
Przedział 52 tyg.: 9.2 - 21.48
Piotroski F-Score: 4
Umiarkowany (średnia jakość finansowa)
EPS: 0.9
P/E branży: 21.3
Beta: 0.936
Raport okresowy: 2025-08-07
WWW: https://www.embecta.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Mr. Jeffrey Z. Mann Senior Vice President, General Counsel, Head of Business Development & Corporate Secretary 959 453 1972
Mr. Shaun Curtis Senior Vice President of Global Manufacturing & Supply Chain 915 666 1969
Mr. Brian R. Capone Vice President, Chief Accounting Officer & Corporate Controller 645 161 1975
Mr. Devdatt Kurdikar President, Chief Executive Officer & Director 2 196 056 1969
Mr. Jacob P. Elguicze Senior Vice President & Chief Financial Officer 1 050 763 1973
Mr. Tom Blount Senior Vice President & President of North America 0 1974
Ms. Jean M. Casner Senior Vice President & Chief Human Resources Officer 0 1958
Ms. Colleen Riley Senior Vice President & Chief Technology Officer 0 1964
Mr. Pravesh Khandelwal Vice President & Head of Investor Relations 0 0
Ms. Ginny Blocki Senior Vice President of Global Marketing & Product Management 0 0
Lista ETF z ekspozycją na akcje Embecta Corp.
Symbol ETF Ilość akcji Wartość
IJR 3 589 526 36 002 950
IWM 1 530 061 15 346 510
VB 1 468 415 15 462 409
VBR 942 075 9 920 049
IJS 567 196 5 688 972
SPSM 502 815 5 116 100
IWN 475 492 4 769 181
SCYB 443 000 400 715
SLYV 319 141 3 244 038
VTWO 294 154 3 097 441
FNDA 283 166 2 744 808
SCHA 273 946 2 827 122
BBHY 212 000 191 562
VIOO 197 168 2 076 179
DES 193 372 1 848 636
JMEE 176 111 1 706 515
VHT 172 615 1 817 635
XHE 172 130 1 787 315
DFAS 134 071 1 383 612
PRFZ 126 637 1 306 893
VIOV 117 995 1 242 487
RWJ 117 086 1 208 327
FSMD 88 107 903 096
IDP6.L 83 495 837 457
IUS3.DE 83 495 837 457
ISP6.L 83 495 837 457
HEAL.L 74 422 746 455
2B78.DE 74 422 746 455
DRDR.L 74 422 746 455
ESML 73 016 753 525
CUS1.L 72 988 732 069
CUSS.L 72 988 732 069
CSUSS.MI 72 988 732 069
SXRG.DE 72 988 732 069
DFAC 69 030 712 389
ITOT 67 184 673 854
EES 64 148 613 254
IWO 62 140 623 266
GSSC 61 308 632 698
PSCH 58 841 607 239
VFMO 55 890 712 597
IUSN.DE 53 737 538 982
WLDS.L 53 737 538 982
WSML.L 53 737 538 982
ISMD 40 771 420 756
VFVA 40 400 515 100
CSD 39 257 405 132
PSC 36 971 378 952
VFMF 36 866 470 041
VTWV 34 786 366 296
RSSL 31 889 338 023
VVL.TO 25 154 461 586
FHLC 23 971 245 702
SMLF 22 332 223 985
IJR.AX 20 449 314 910
ROSC 20 191 206 957
IWV 16 445 164 944
WSCR.L 16 416 169 412
TILT 16 120 170 872
XB 15 000 0
DFUS 13 912 143 571
AGNG 13 343 141 435
SPTM 10 772 108 030
XSU.TO 10 538 144 157
ISCV 10 492 105 233
DFAU 10 156 104 809
QVMS 9 837 101 517
HEJD 6 897 71 177
VMO.TO 6 224 114 213
UWM 5 923 61 125
URTY 4 917 50 743
VTWG 4 865 51 228
DTD 4 676 44 702
VTHR 4 651 48 975
FLQS 4 600 47 012
XJR 4 583 47 296
QQQS 3 553 36 666
DFSU 3 365 34 726
OMFS 2 586 26 687
ISCB 2 523 25 304
VLU 2 474 24 899
XEQT.TO 2 431 33 260
XUU.TO 2 337 33 936
FNDB 2 318 22 461
DCOR 2 209 22 796
XSMC.TO 2 081 28 471
XSMH.TO 1 976 27 036
XAW.TO 1 881 25 728
SPGM 1 500 15 068
PINK 1 383 14 175
SAA 1 060 10 939
EBIT 620 6 355
ESIX 449 4 557
XBAL.TO 376 5 458
XUH.TO 333 3 341
MMTM 235 2 354
HDG 73 753
XSC.TO 46 5 630
XTR.TO 14 144
DXUV 8 82
PZW.TO 0 0
USUE.DE 0 0
USFM.L 0 0
Wiadomości dla Embecta Corp.
Tytuł Treść Źródło Aktualizacja Link
Embecta Corp. (EMBC) Q2 2025 Earnings Call Transcript Embecta Corp. (NASDAQ:EMBC ) Q2 2025 Earnings Conference Call May 9, 2025 8:00 AM ET Company Participants Dev Kurdikar - President & CEO Jake Elguicze - CFO Pravesh Khandelwal - Vice VP, IR Conference Call Participants Kallum Titchmarsh - Morgan Stanley Marie Thibault - BTIG Anthony Petrone - Mizuho Securities Michael Polark - Wolfe Research Operator Welcome, ladies and gentlemen, to Embecta Corp.'s fiscal second quarter 2025 earnings conference call. At this time, all participants have been placed in a listen-only mode. seekingalpha.com 2025-05-09 17:39:46 Czytaj oryginał (ang.)
Embecta Corp. (EMBC) Tops Q2 Earnings Estimates Embecta Corp. (EMBC) came out with quarterly earnings of $0.70 per share, beating the Zacks Consensus Estimate of $0.66 per share. This compares to earnings of $0.67 per share a year ago. zacks.com 2025-05-09 12:40:40 Czytaj oryginał (ang.)
Embecta Corp. Reports Second Quarter Fiscal 2025 Financial Results PARSIPPANY, N.J., May 09, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta” or the "Company") (Nasdaq: EMBC), a global diabetes care company, today reported financial results for the three and six month periods ended March 31, 2025. globenewswire.com 2025-05-09 10:30:00 Czytaj oryginał (ang.)
embecta Announces Quarterly Cash Dividend PARSIPPANY, N.J., May 09, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. (“embecta”) (Nasdaq: EMBC) has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company's common stock. The dividend is payable on June 13, 2025 to stockholders of record at the close of business on May 28, 2025. globenewswire.com 2025-05-09 10:00:00 Czytaj oryginał (ang.)
Embecta to host Analyst and Investor Day on May 22, 2025 PARSIPPANY, N.J., April 28, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will hold an Analyst and Investor Day on May 22, 2025, from 9:00 a.m. to 12:30 p.m. in New York City. globenewswire.com 2025-04-28 11:30:00 Czytaj oryginał (ang.)
embecta to Report Fiscal Second Quarter 2025 Financial Results PARSIPPANY, N.J., April 21, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will host a conference call to discuss its fiscal second quarter 2025 financial results, provide an operational update, and host a question and answer session, at 8:00 a.m. Eastern Time (ET) on Friday, May 9, 2025. globenewswire.com 2025-04-21 21:00:00 Czytaj oryginał (ang.)
Mayo Clinic Proceedings Publishes New Global Insulin Injection Recommendations PARSIPPANY, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, today announced a new landmark publication in the Mayo Clinic Proceedings. globenewswire.com 2025-04-01 12:05:00 Czytaj oryginał (ang.)
Embecta: Weak Outlook But Mouth-Watering Valuation Skew Risk-Reward In Favour Embecta faces headwinds from new insulin delivery technologies and GLP-1 drugs, but its valuation is compelling with a ~44% free cash flow yield on guided free cashflow. EMBC's end market is expected to witness a headwind from increased use of pump patches in comparison to traditional insulin delivery routes. Moreover, increased GLP-1 use to treat diabetes would lead to further less frequent use of EMBC's product. seekingalpha.com 2025-02-28 04:17:38 Czytaj oryginał (ang.)
embecta to Participate at the J.P. Morgan Global Leveraged Finance Conference PARSIPPANY, N.J., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. (embecta) (Nasdaq: EMBC) today announced that Jake Elguicze, embecta's Chief Financial Officer, will present at the J.P. Morgan Global Leveraged Finance Conference in Miami on Tuesday, February 25, 2025 at 3:00 p.m. ET. globenewswire.com 2025-02-18 19:00:00 Czytaj oryginał (ang.)
Embecta Corp. (EMBC) Q1 2025 Earnings Call Transcript Embecta Corp. (NASDAQ:EMBC ) Q1 2025 Earnings Conference Call February 6, 2025 8:00 AM ET Company Participants Pravesh Khandelwal - Vice President, Investor Relations Dev Kurdikar - President & Chief Executive Officer Jake Elguicze - Chief Financial Officer Conference Call Participants Kallum Titchmarsh - Morgan Stanley Ryan Schiller - Wolfe Research Operator Good day, and thank you for standing by. Welcome, ladies and gentlemen, to the Embecta Fiscal First Quarter 2025 Earnings Conference Call. seekingalpha.com 2025-02-06 15:55:18 Czytaj oryginał (ang.)
Embecta Corp. (EMBC) Tops Q1 Earnings and Revenue Estimates Embecta Corp. (EMBC) came out with quarterly earnings of $0.65 per share, beating the Zacks Consensus Estimate of $0.45 per share. This compares to earnings of $0.61 per share a year ago. zacks.com 2025-02-06 10:45:40 Czytaj oryginał (ang.)
Embecta Corp. Reports First Quarter Fiscal 2025 Financial Results PARSIPPANY, N.J., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta” or the "Company") (Nasdaq: EMBC), a global diabetes care company, today reported financial results for the three month period ended December 31, 2024. globenewswire.com 2025-02-06 08:30:00 Czytaj oryginał (ang.)
embecta Announces Quarterly Cash Dividend PARSIPPANY, N.J., Feb. 06, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. (“embecta”) (Nasdaq: EMBC) has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company's common stock. The dividend is payable on March 14, 2025 to stockholders of record at the close of business on February 28, 2025. globenewswire.com 2025-02-06 08:00:00 Czytaj oryginał (ang.)
embecta to Report Fiscal First Quarter 2025 Financial Results PARSIPPANY, N.J., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will host a conference call to discuss its fiscal first quarter 2025 financial results, provide an operational update, and host a question and answer session, at 8:00 a.m. Eastern Time (ET) on Thursday, February 6, 2025. globenewswire.com 2025-01-23 19:00:00 Czytaj oryginał (ang.)
The Zacks Analyst Blog Doximity, Omnicell, Embecta, Cencora and EDOC Doximity, Omnicell, Embecta, Cencora and EDOC are included in this Analyst Blog. zacks.com 2025-01-23 06:45:27 Czytaj oryginał (ang.)
4 MedTech Stocks Poised to Thrive Under Second Trump Presidency Four MedTech stocks that are set to benefit from Trump 2.0 are DOCS, OMCL, EMBC and COR. zacks.com 2025-01-22 14:56:10 Czytaj oryginał (ang.)
3 Stocks Trading Near 52-Week High With Room to Rise Further Investors target stocks that have been on a bullish run lately. Stocks like EMBC, NFG and REVG are seeing price strength and the momentum is likely to continue. zacks.com 2025-01-06 11:36:17 Czytaj oryginał (ang.)
3 Medical Services Stocks to Buy to Counter Labor Shortage Woes The Zacks Medical - Services industry is growing on nursing care market growth and digital healthcare adoption. DOCS, BTSG and EMBC are set to gain the most. zacks.com 2025-01-03 06:31:11 Czytaj oryginał (ang.)
4 Best-Bargain PEG Stocks That Value Investors Love Here are four stocks that fit our screening criteria. These are GAP, EMBC, BLBD and ZIM. zacks.com 2024-12-23 11:51:39 Czytaj oryginał (ang.)
embecta to Participate at the 43rd Annual J.P. Morgan Healthcare Conference PARSIPPANY, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. (embecta) (Nasdaq: EMBC) today announced that management will present at the J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 15, 2025 at 7:30 a.m. PT / 10:30 a.m. ET. globenewswire.com 2024-12-19 19:00:00 Czytaj oryginał (ang.)
New Initiatives Expected To Make Embecta More Profitable Embecta Corp.'s Q4 results showed significant net income and EPS growth as well as profitability plans, and drove up the share price. The company announced a restructuring plan to streamline operations, reduce costs by up to $65 million annually, and discontinue its insulin patch pump program. Embecta aims to strengthen its core business, expand its GLP-1 therapies portfolio, and reduce debt, positioning it for profitable growth in fiscal 2025. seekingalpha.com 2024-12-04 10:30:00 Czytaj oryginał (ang.)
New Strong Buy Stocks for December 2nd EMBC, TOST, MNDY, NTRS and MANU have been added to the Zacks Rank #1 (Strong Buy) List on December 2, 2024. zacks.com 2024-12-02 09:56:07 Czytaj oryginał (ang.)
Best Value Stocks to Buy for December 2nd EMBC, BLBD and ENVA made it to the Zacks Rank #1 (Strong Buy) value stocks list on December 2, 2024. zacks.com 2024-12-02 07:21:08 Czytaj oryginał (ang.)
Best Income Stocks to Buy for December 2nd CTBI and EMBC made it to the Zacks Rank #1 (Strong Buy) income stocks list on December 2, 2024. zacks.com 2024-12-02 07:16:08 Czytaj oryginał (ang.)
Overlooked Stock: EMBC Bad news is good news? Appears to be the case for medical device company Embecta (EMBC) as shares soared after it stopped its insulin patch pump program. youtube.com 2024-11-27 18:38:18 Czytaj oryginał (ang.)
Embecta Corp. (EMBC) Q4 2024 Earnings Call Transcript Embecta Corp. (NASDAQ:EMBC ) Q4 2024 Earnings Conference Call November 26, 2024 8:00 AM ET Company Participants Pravesh Khandelwal - VP of IR Dev Kurdikar - President and CEO Jake Elguicze - CFO Conference Call Participants Marie Thibault - BTIG Operator Good day, and welcome to the Embecta Fourth Quarter of Fiscal Year 2024 Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. seekingalpha.com 2024-11-26 16:04:17 Czytaj oryginał (ang.)
Becton Dickinson Spinoff Embecta Stops Insulin Patch Pump Program, Plans Restructuring, Stock Jumps On Tuesday, Embecta Corp EMBC posted the fourth-quarter adjusted EPS of 45 cents, beating the consensus of 36 cents and down from 59 cents reported a year ago. benzinga.com 2024-11-26 15:15:05 Czytaj oryginał (ang.)
Embecta Corp. (EMBC) Tops Q4 Earnings and Revenue Estimates Embecta Corp. (EMBC) came out with quarterly earnings of $0.45 per share, beating the Zacks Consensus Estimate of $0.40 per share. This compares to earnings of $0.59 per share a year ago. zacks.com 2024-11-26 10:41:17 Czytaj oryginał (ang.)
Embecta Corp. Reports Fiscal 2024 Fourth Quarter and Full Year Financial Results; Provides Initial Fiscal Year 2025 Financial Guidance; Discontinues Insulin Patch Pump Program; and Announces Restructuring to Streamline Operations and Reduce Costs PARSIPPANY, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta” or the "Company") (Nasdaq: EMBC), a global diabetes care company, today reported financial results for the three- and twelve-month periods ended September 30, 2024. globenewswire.com 2024-11-26 08:30:00 Czytaj oryginał (ang.)
embecta Announces Quarterly Cash Dividend PARSIPPANY, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. (“embecta”) (Nasdaq: EMBC) has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company's common stock. The dividend is payable on December 18, 2024 to stockholders of record at the close of business on December 6, 2024. globenewswire.com 2024-11-26 08:00:00 Czytaj oryginał (ang.)
UPDATE - embecta to Report Fiscal Fourth Quarter and Full Year 2024 Financial Results PARSIPPANY, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will host a conference call to discuss its fiscal fourth quarter and full year 2024 financial results, and provide an operational update, including preliminary fiscal year 2025 financial guidance, at 8:00 a.m. Eastern Time (ET) on Tuesday, November 26, 2024. globenewswire.com 2024-11-12 19:31:00 Czytaj oryginał (ang.)
embecta to Report Fiscal Fourth Quarter and Full Year 2024 Financial Results PARSIPPANY, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will host a conference call to discuss its fiscal fourth quarter and full year 2024 financial results, and provide an operational update, including preliminary fiscal year 2025 financial guidance, at 8:00 a.m. Eastern Time (ET) on Thursday, November 26, 2024. globenewswire.com 2024-11-12 19:00:00 Czytaj oryginał (ang.)
embecta Celebrates National Diabetes Awareness Month by Ringing Nasdaq Closing Bell embecta will be joined by diabetes advocacy groups to ring the Nasdaq Closing Bell today in recognition of National Diabetes Awareness Month in November. globenewswire.com 2024-11-07 08:30:00 Czytaj oryginał (ang.)
Embecta Stock Gains on FDA Clearance for Type 2 Diabetes Insulin Pump EMBC's shares close higher following FDA clearance for its disposable patch pump for insulin delivery, expanding the target market with its availability for type 2 diabetes. zacks.com 2024-09-04 13:26:38 Czytaj oryginał (ang.)
embecta Announces FDA Clearance of its Disposable Patch Pump for Insulin Delivery Informed by the Unique Needs of People with Type 2 Diabetes embecta has received 510(k) clearance from the FDA for its proprietary disposable insulin delivery system, a patch pump with a 300-unit insulin reservoir. globenewswire.com 2024-09-03 10:30:00 Czytaj oryginał (ang.)
embecta to Participate in Investor Events PARSIPPANY, N.J., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, today announced that management will participate in the following investor events: globenewswire.com 2024-08-22 21:00:00 Czytaj oryginał (ang.)
Embecta Corp. (EMBC) Just Overtook the 200-Day Moving Average From a technical perspective, Embecta Corp. (EMBC) is looking like an interesting pick, as it just reached a key level of support. EMBC recently overtook the 200-day moving average, and this suggests a long-term bullish trend. zacks.com 2024-08-12 14:30:46 Czytaj oryginał (ang.)